Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience

03-05-2024 | Antidepressant Drugs | Original Paper

Smoking may increase the usage of antidepressant: evidence from genomic perspective analysis

Authors: Yucai Qu, Zhiqiang Du, Yuan Shen, Qin Zhou, Zhenhe Zhou, Ying Jiang, Haohao Zhu

Published in: European Archives of Psychiatry and Clinical Neuroscience

Login to get access

Abstract

This study uses the two-sample Mendelian randomization (TSMR) method to explore the causal relationships between smoking initiation (SMKI), never smoking (NSMK), past tobacco smoking (PTSMK), and the usage of antidepressants (ATD). Single-nucleotide polymorphisms (SNPs) with genome-wide significance (P < 5E−08) related to SMKI, NSMK, and PTSMK were selected from the genome-wide association study (GWAS) database as instrumental variables (IVs). The main method, inverse variance weighted (IVW), was utilized to investigate the causal relationship. The results demonstrated a positive causal relationship between SMKI and ATD use, where SMKI leads to an increase in ATD use. Conversely, NSMK and PTSMK showed a negative causal relationship with ATD use, meaning that NSMK and PTSMK lead to a reduction in ATD use. Additionally, sensitivity analysis showed that the results of this study were robust and reliable. Using the TSMR method and from a genetic perspective, this study found that SMKI leads to an increase in ATD use, while NSMK and PTSMK reduce ATD use.
Literature
1.
Richardson S, McNeill A, Brose LS (2019) Smoking and quitting behaviours by mental health conditions in Great Britain (1993–2014). Addict Behav 90:14–19PubMedPubMedCentralCrossRef
2.
3.
Mao Y, Zhang N, Liu J et al (2019) A systematic review of depression and anxiety in medical students in China. BMC Med Educ 19(1):1–13CrossRef
4.
Shorey S, Ng ED, Wong CHJ (2022) Global prevalence of depression and elevated depressive symptoms among adolescents: a systematic review and meta-analysis. Br J Clin Psychol 61(2):287–305PubMedCrossRef
5.
Centers for Disease Control and Prevention (CDC) (2008) Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. MMWR Morb Mortal Wkly Rep 57(45):1226–1228
6.
7.
Lasser K, Boyd JW, Woolhandler S et al (2000) Smoking and mental illness: a population-based prevalence study. JAMA 284(20):2606–2610PubMedCrossRef
8.
Oliveira P, Ribeiro J, Donato H et al (2017) Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry 16:1–8CrossRef
9.
Korhonen T, Loukola A, Wedenoja J et al (2014) Role of nicotine dependence in the association between the dopamine receptor gene DRD3 and major depressive disorder. PLoS One 9(6):e98199PubMedPubMedCentralCrossRef
10.
Broms U, Wedenoja J, Largeau MR et al (2012) Analysis of detailed phenotype profiles reveals CHRNA5-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits. Nicotine Tob Res 14(6):720–733PubMedPubMedCentralCrossRef
11.
Korhonen T, Koivumaa-Honkanen H, Varjonen J et al (2011) Cigarette smoking and dimensions of depressive symptoms: longitudinal analysis among Finnish male and female twins. Nicotine Tob Res 13(4):261–272PubMedCrossRef
12.
Hahad O, Beutel M, Gilan DA et al (2022) The association of smoking and smoking cessation with prevalent and incident symptoms of depression, anxiety, and sleep disturbance in the general population. J Affect Disord 313:100–109PubMedCrossRef
13.
Kagabo R, Gordon AJ, Okuyemi K (2020) Smoking cessation in inpatient psychiatry treatment facilities: a review. Addict Behav Rep 11:100255PubMedPubMedCentral
14.
15.
Arias HR, Targowska-Duda KM, García-Colunga J et al (2021) Is the antidepressant activity of selective serotonin reuptake inhibitors mediated by nicotinic acetylcholine receptors? Molecules 26(8):2149PubMedPubMedCentralCrossRef
16.
Husky MM, Mazure CM, Paliwal P et al (2008) Gender differences in the comorbidity of smoking behavior and major depression. Drug Alcohol Depend 93(1–2):176–179PubMedCrossRef
17.
Spring B, Pingitore R, McChargue DE (2003) Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers. Am J Psychiatry 160(2):316–322PubMedCrossRef
18.
Royal College of Psychiatrists (2013) Smoking and Mental Health. Royal College of Physicians, London
19.
Korhonen T, Ranjit A, Tuulio-Henriksson A et al (2017) Smoking status as a predictor of antidepressant medication use. J Affect Disord 207:221–227PubMedCrossRef
20.
Chéron-Launay M, Le Faou AL, Sévilla-Dedieu C et al (2011) Smoking and the consumption of antidepressants, anxiolytics and hypnotic drugs: results of a large, French epidemiological study in 2005. Addict Behav 36(7):743–748PubMedCrossRef
21.
Skrivankova VW, Richmond RC, Woolf BAR et al (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 375:n2233PubMedPubMedCentralCrossRef
22.
23.
Zhu H, Sun Y, Guo S et al (2023) Causal relationship between sex hormone-binding globulin and major depression: A Mendelian randomization study. Acta Psychiatr Scand 148(5):426–436PubMedCrossRef
24.
Zhu H, Lu R, Zhou Q et al (2023) Relationship between sphingomyelin and risk of Alzheimer’s disease: a bidirectional mendelian randomization study. J Alzheimer’s Dis Rep 7(1):1289–1297CrossRef
25.
Du Z, Guo S, Sun Y et al (2023) Causal relationships between dietary habits and five major mental disorders: a two-sample Mendelian randomization study. J Affect Disord 340:607–615PubMedCrossRef
26.
Ji Y, Du Z, Zheng K et al (2023) Bidirectional causal association between ischemic stroke and five mental disorders. Acta Psychiatr Scand 148(4):359–367PubMedCrossRef
27.
Sekula P, Fabiola Del Greco M, Pattaro C et al (2016) Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 27(11):3253PubMedPubMedCentralCrossRef
28.
Liu M, Jiang Y, Wedow R et al (2019) Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet 51(2):237–244PubMedPubMedCentralCrossRef
29.
Bowden J, Del Greco MF, Minelli C et al (2016) Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 45(6):1961–1974PubMedPubMedCentral
30.
Burgess S, Dudbridge F, Thompson SG (2016) Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med 35(11):1880–1906PubMedCrossRef
31.
Bowden J, Del Greco MF, Minelli C et al (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 36(11):1783–1802PubMedPubMedCentralCrossRef
32.
Bowden J, Davey Smith G, Haycock PC et al (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40(4):304–314PubMedPubMedCentralCrossRef
33.
Yuan S, Carter P, Mason AM et al (2022) Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk. Arthritis Rheumatol 74(10):1638–1647PubMedPubMedCentralCrossRef
34.
Nolte IM (2020) Metasubtract: an R-package to analytically produce leave-one-out meta-analysis GWAS summary statistics. Bioinformatics 36(16):4521–4522PubMedPubMedCentralCrossRef
35.
Rognli EB, Bramness JG, von Soest T (2022) Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics. Psychol Med 52(14):3241–3250PubMedCrossRef
36.
37.
Bousman CA, Stevenson JM, Ramsey LB et al (2023) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 114:51–68PubMedCrossRef
38.
Protti M, Mandrioli R, Marasca C et al (2020) New-generation, non-SSRI antidepressants: drug–drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Med Res Rev 40(5):1794–1832PubMedCrossRef
39.
Austin-Zimmerman I, Wronska M, Wang B et al (2021) The influence of CYP2D6 and CYP2C19 genetic variation on diabetes mellitus risk in people taking antidepressants and antipsychotics. Genes 12(11):1758PubMedPubMedCentralCrossRef
40.
Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(01/02):9–62PubMedCrossRef
41.
Al-Arifi MN, Maayah ZH, AlShamrani AA et al (2012) Impact of cigarette smoke exposure on the expression of cardiac hypertrophic genes, cytochrome P450 enzymes, and oxidative stress markers in rats. J Toxicol Sci 37(5):1083–1090PubMedCrossRef
42.
Scherf-Clavel M, Samanski L, Hommers LG et al (2019) Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Int Clin Psychopharmacol 34(2):93–100PubMedCrossRef
43.
Desai HD, Seabolt J, Jann MW (2001) Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 15:469–494PubMedCrossRef
44.
Augustin M, Schoretsanitis G, Hiemke C et al (2018) Differences in duloxetine dosing strategies in smoking and nonsmoking patients: therapeutic drug monitoring uncovers the impact on drug metabolism. J Clin Psychiatry 79(5):17m12086PubMedCrossRef
45.
Zevin S, Benowitz NL (1999) Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 36:425–438PubMedCrossRef
46.
Wium-Andersen MK, Ørsted DD, Nielsen SF et al (2013) Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA Psychiat 70(2):176–184CrossRef
47.
Barbosa ML, de Meneses AAPM, de Aguiar RPS et al (2020) Oxidative stress, antioxidant defense and depressive disorders: a systematic review of biochemical and molecular markers. Neurol Psychiatry Brain Res 36:65–72CrossRef
Metadata
Title
Smoking may increase the usage of antidepressant: evidence from genomic perspective analysis
Authors
Yucai Qu
Zhiqiang Du
Yuan Shen
Qin Zhou
Zhenhe Zhou
Ying Jiang
Haohao Zhu
Publication date
03-05-2024
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-024-01802-2